- Add-on nemolizumab is associated with clinical benefit in patients with moderate to severe atopic dermatitis (AD) inadequately controlled with topical corticosteroids (TCS), according to data from a phase 2b randomised controlled trial.
Why this matters
- Nemolizumab offers a novel mechanism for AD treatment and has already shown efficacy as monotherapy.
- 226 patients with TCS-refractory moderate to severe AD and severe pruritus were assigned to receive nemolizumab (10, 30, or 90 mg; n=169) or placebo (n=57) in addition to TCS.
- Funding: Nestlé Skin Health–Galderma R&D.
- Nemolizumab 30 mg was associated with improved Eczema Area and Severity Index (EASI) compared with placebo at week 16 (P<.01 and week>
- Nemolizumab 30 mg was associated with improved rates of >50% improvement in EASI (EASI-50) compared with placebo at week 16 (P=.016) and week 24 (P=.014).
- Nemolizumab 30 mg was associated with improvements in peak pruritus numeric rating scale compared with placebo at week 16 (P≤.001) and week 24 (P≤.001).
- Serious treatment-emergent adverse events were reported in 5.5% of patients receiving nemolizumab 10 mg, 3.5% of patients receiving nemolizumab 30 or 90 mg, and 1.8% of patients receiving placebo.
- Relatively short follow-up.
- Small sample size.